The phase 2 trial showed a 42% response rate with lete-cel in synovial sarcoma and MRCLS, with manageable adverse events.

Earlier this week, the American Cancer Society released the full list of 245 new and renewed research grants that were ...

In a recent transaction, William C. Bertrand Jr., the Chief Operating Officer of Adaptimmune Therapeutics PLC (NASDAQ:ADAP), ...

Officer of Adaptimmune Therapeutics PLC (NASDAQ:ADAP), executed a sale of 5,584 American Depositary Shares (ADS) on January ...

In oncology, she highlighted MDM2-p53 antagonist brigimadlin, which has advanced into a pivotal trial for dedifferentiated liposarcoma, a rare cancer with limited treatment options so far ...

Under the agreement, AGC Biologics will manufacture the lentiviral vector used to produce lete-cel, an engineered T-cell ...

The more than $45,000 raised through a GoFundMe page (gofundme.com/f/brrkt6-support-rods-fight-against-cancer) is helping to ...

The firm is aiming to break even on its cash flow by 2027 by narrowing its focus on its sarcoma treatments and pipeline candidates with the greatest potential.

aDepartment of Medical Oncology, National Cancer Center Hospital, Tokyo 104-0045, Japan ...

A breakthrough in Russia promises to redefine cancer treatment, with the country announcing its first mRNA cancer vaccine.